Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of treatment that doctors hope will work against many types of tumors. https://cnn.it/4g6rgdy

How each outlet headlined it

• CNN left

  Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of treatment that doctors hope will work against many types of tumors. https://cnn.it/4g6rgdy
• The Economist center

  The success in a trial of intismeran, a vaccine for melanoma, is good news. But is it a one-off, or will it open a portal to a new way of treating cancers in general?
• Bloomberg center

  Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marve
• The Wall Street Journal right

  After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win. on.wsj.com/4zxBco2